IMAB

I-MAB

1.53 USD

Last updated Dec 10, 08:25 UTC

Yesterday HIGH

$1.56

Yesterday LOW

$1.48

52w HIGH

$7.67

52w LOW

$1.16

EPS

-1.05

PE

-1.46

Next Earnings

Apr 1, 2024

Overview News Government Trades

I-MAB stock is down -2.55% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November.

I-Mab discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases. Its product candidates also includes Enoblituzumab, which has completed Phase 2 clinical trials for head and neck cancer, and other oncology diseases.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

i-mabbiopharma.com

richadhand@benzinga.com

Fri Aug 18, 2023

Needham Reiterates Buy on I-MAB, Maintains $24 Price Target

Needham analyst Gil Blum reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $24 price target.
Benzinga Newsdesk

Thu Aug 17, 2023

I-MAB H1 EPS $(0.46) Up From $(0.62) YoY, Sales $2.71M Down From $7.74M YoY

I-MAB (NASDAQ:IMAB) reported quarterly losses of $(0.46) per share. This is a 25.81 percent increase over losses of $(0.62) per share from the same period last year. The company reported $2.71 million in sales this
Benzinga Insights

Mon Aug 14, 2023

Stocks That Hit 52-Week Lows On Monday

During Monday's session, 201 stocks hit new 52-week lows.
Benzinga Insights

Wed Aug 9, 2023

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 155 companies set new 52-week lows.
Benzinga Insights

Tue Aug 8, 2023

Stocks That Hit 52-Week Lows On Tuesday

During Tuesday's trading, 188 companies set new 52-week lows.
Benzinga Insights

Thu Jul 6, 2023

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 109 companies set new 52-week lows.
Happy Mohamed

Wed Jul 5, 2023

I-Mab Announces Publication Of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig In JITC

I-Mab (the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the
Bill Haddad

Thu Jun 22, 2023

I-Mab Announces Appointment Of Raj Kannan As CEO
Benzinga Newsdesk

Thu Jun 15, 2023

TRACON Commences Court Proceedings In Hong Kong And Cayman Islands To Enforce Apr. 2023 Arbitration Award Against I-Map For ~$23M Plus Intersest
Benzinga Insights

Mon Jun 5, 2023

5 Analysts Have This to Say About I-MAB